8 potential new medicines in clinical development prioritizing treatment for vulnerable populations and supporting malaria eradication

MMV and partners manage a portfolio of more than 65 projects, the largest portfolio of antimalarial R&D and access projects ever assembled.

The portfolio includes eight new drugs in clinical development addressing unmet medical needs in malaria, including medicines for children, pregnant women and relapsing malaria, and drugs that could support the elimination/eradication agenda. 

Go to MMV's portfolio to learn more.

Updated July 2017